The role of proprotein convertase subtilisin-kexin type 9 (PCSK9) in the vascular aging process – is there a link?
Lately there are many new, promising low-density lipoprotein cholesterol reducing therapies with PCSK9 inhibitors. We performed selected sampling of the publications in PubMed and made a review according to selected keywords. It summarizes the effect of PCSK9 on vascular aging, directly associated w...
Main Authors: | Malwina Grobelna, Ewa Strauss, Zbigniew Krasiński |
---|---|
Format: | Article |
Language: | English |
Published: |
Termedia Publishing House
2019-10-01
|
Series: | Polish Journal of Thoracic and Cardiovascular Surgery |
Subjects: | |
Online Access: | https://www.termedia.pl/The-role-of-proprotein-convertase-subtilisin-kexin-type-9-PCSK9-in-the-vascular-aging-process-is-there-a-link-,40,37944,1,1.html |
Similar Items
-
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in the treatment of dyslipidemia
by: A. A. Shikaleva, et al.
Published: (2021-01-01) -
Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Beyond Lipids: The Role in Oxidative Stress and Thrombosis
by: Vittoria Cammisotto, et al.
Published: (2022-03-01) -
Egyptian Association of Vascular Biology and Atherosclerosis (EAVA) consensus on the usage of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors
by: Ashraf Reda, et al.
Published: (2020-05-01) -
Proprotein Convertase Subtilisin/Kexin 9 as a Modifier of Lipid Metabolism in Atherosclerosis
by: Anastasia V. Poznyak, et al.
Published: (2023-02-01) -
Hepatocellular carcinoma-associated hypercholesterolemia: involvement of proprotein-convertase-subtilisin-kexin type-9 (PCSK9)
by: Dipti Athavale, et al.
Published: (2018-10-01)